Breast cancer showed significant antitumor effects47; in colorectal cancer studies, overexpression of SIRT4 was found to inhibit the metabolism of glutamine while also inhibiting the proliferation of rectal cancer cells through synergistic glucose inhibitors48; glutamine transporter protein inhibitor V‐9302 was able to selectively block triple‐negative breast cancer (TNBC) cells' glutamine uptake and simultaneously enhance the immune response of T cells, suggesting that preferential inhibition of glutamine metabolism in tumor cells may represent a promising targeted therapy.49 Here, SIRT4 is linked to breast carcinoma.